↓ Skip to main content

HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor

Overview of attention for article published in Molecular Cancer Therapeutics, January 2007
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#18 of 3,686)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
1 news outlet
twitter
18 tweeters
facebook
573 Facebook pages
wikipedia
1 Wikipedia page
googleplus
27 Google+ users
video
1 video uploader

Citations

dimensions_citation
53 Dimensions

Readers on

mendeley
81 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor
Published in
Molecular Cancer Therapeutics, January 2007
DOI 10.1158/1535-7163.mct-06-0039
Pubmed ID
Authors

Natalya M. Kogan, Michael Schlesinger, Esther Priel, Ruth Rabinowitz, Eduard Berenshtein, Mordechai Chevion, Raphael Mechoulam

Abstract

Anthracyclines, a large group of quinonoid compounds, are used to treat some forms of cancer. Although highly effective in cancer therapy, the mechanism of action of these compounds is not specific; they act on cancer and other cells by numerous mechanisms. A new anticancer quinone (HU-331) was synthesized from cannabidiol. It shows significant high efficacy against human cancer cell lines in vitro and against in vivo tumor grafts in nude mice. In this study, we investigated its mode of action and present evidence on its unique mechanism. HU-331 does not cause cancer cell cycle arrest, cell apoptosis, or caspase activation. HU-331-caused cell death of human cancer cell lines is not mediated by reactive oxygen intermediates/species, as exposure to HU-331 failed to elicit the generation of reactive oxygen species. HU-331 inhibits DNA topoisomerase II even at nanomolar concentrations but has only a slight nonsignificant effect on DNA topoisomerase I action. The cannabinoid quinone HU-331 is a highly specific inhibitor of topoisomerase II, compared with most known anticancer quinones. It might represent a new potent anticancer drug.

Twitter Demographics

The data shown below were collected from the profiles of 18 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
Costa Rica 1 1%
India 1 1%
Spain 1 1%
United Kingdom 1 1%
Unknown 75 93%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 17 21%
Researcher 12 15%
Student > Bachelor 10 12%
Student > Master 7 9%
Other 6 7%
Other 12 15%
Unknown 17 21%
Readers by discipline Count As %
Chemistry 15 19%
Medicine and Dentistry 11 14%
Biochemistry, Genetics and Molecular Biology 10 12%
Agricultural and Biological Sciences 9 11%
Pharmacology, Toxicology and Pharmaceutical Science 5 6%
Other 8 10%
Unknown 23 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 195. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 May 2022.
All research outputs
#147,448
of 21,380,143 outputs
Outputs from Molecular Cancer Therapeutics
#18
of 3,686 outputs
Outputs of similar age
#577
of 140,438 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#1
of 60 outputs
Altmetric has tracked 21,380,143 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,686 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 140,438 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 60 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.